According to Hovione Technology, the company has received patent grants for its TwinMax large dose DPI in a number of new territories. CEO Peter Villax said, “We achieved unchallenged patent grants for TwinMax in the United States, Europe, Japan, China and other territories. Our patented TwinMax will enable pharmaceutical partners to license them and to develop and take forward to the market new drugs requiring delivery of large lung doses.”
The TwinMax device can deliver doses as large as 100 mg, in 2 inhalations of 50 mg each. Hovione Technology Director of Technology Development and Licensing João Ventura Fernandes explained, “The patient simply needs to perform one use step and the large target dose is delivered from 2 puffs to make delivery comfortable. We have designed an enhanced inhaler engine for large dose delivery, while keeping the overall usability of TwinCaps, the world’s leading disposable inhaler with an experience of 10 years treating patients in Japan.”
In August 2019, Hovione Technology announced that it had partnered with Kiel University for development of dry powder formulations of high dose antibiotics for use with the TwinMax and 8Shot large dose DPIs. The 8Shot device can deliver up to 400 mg in 8 doses of 50 mg each.
Read the Hovione Technology press release.
